In an exclusive Chemistry Today post-CPHI roundtable, Minjeong Seong, Director of Market Intelligence, shares insights on the structural shifts transforming biopharmaceutical manufacturing. She highlights that industry value is moving beyond speed and cost toward supply-chain resilience, sustainability, and security of supply. As modalities diversify and demand surges across therapies like GLP-1s, expanding capacity alone is no longer enough. Instead, drug developers must engage CDMO partners early in process design to ensure multisite quality alignment, regulatory readiness, and tech-transfer feasibility.
Read the full roundtable discussion on Chemistry Today.
In an exclusive Chemistry Today post-CPHI roundtable, Minjeong Seong, Director of Market Intelligence, shares insights on the structural shifts transforming biopharmaceutical manufacturing. She highlights that industry value is moving beyond speed and cost toward supply-chain resilience, sustainability, and security of supply. As modalities diversify and demand surges across therapies like GLP-1s, expanding capacity alone is no longer enough. Instead, drug developers must engage CDMO partners early in process design to ensure multisite quality alignment, regulatory readiness, and tech-transfer feasibility.
Read the full roundtable discussion on Chemistry Today.
Share article
Related Content